TY - JOUR
T1 - Comparison of fasting human pancreatic polypeptide levels among patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, and type 2 diabetes mellitus
AU - Nagpal, Sajan Jiv Singh
AU - Bamlet, William R.
AU - Kudva, Yogish C.
AU - Chari, Suresh T.
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.
AB - Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.
KW - chronic pancreatitis
KW - pancreatic cancer
KW - pancreatic polypeptide
KW - type 3c diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85049039344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049039344&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001077
DO - 10.1097/MPA.0000000000001077
M3 - Article
C2 - 29771765
AN - SCOPUS:85049039344
SN - 0885-3177
VL - 47
SP - 738
EP - 741
JO - Pancreas
JF - Pancreas
IS - 6
ER -